Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan [TechCrunch]

Unity Biotechnology, Inc. (UBX)
Last unity biotechnology, inc. earnings: 3/11 04:05 pm
Check Earnings Report
Company Research
Source: TechCrunch
Altman previously provided Retro Biosciences' entire seed round of $180 million. Now, the startup is raising a $1 billion Series A that Altman is joining, the Financial Times reports. Retro Biosciences, which says it plans to launch trials for drugs targeting diseases like Alzheimer's, recently trained a model with OpenAI to turn regular cells into stem cells. CEO Joe Betts-LaCroix told the FT he wants to move fast by discovering and developing a drug “in the 2020s.” The startup joins other major billionaire-backed longevity efforts, including Altos Labs, which launched with $3 billion in 2022 backed by Jeff Bezos, and Unity Biotechnology, supported by both Bezos and Peter Thiel.
Show less
Read more
Impact Snapshot
Event Time:
UBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UBX alerts
High impacting Unity Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
UBX
News
- Unity Biotechnology, Inc. (NASDAQ: UBX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- UNITY Biotechnology Reports Granting of New Employment Inducement AwardGlobeNewswire
- UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical OfficerGlobeNewswire
UBX
Earnings
- 5/14/24 - Beat
UBX
Sec Filings
- 2/5/25 - Form 4
- 2/5/25 - Form 4
- 2/5/25 - Form 4
- UBX's page on the SEC website